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Abstract 1 
 2 
Context: Hajdu-Cheney syndrome (HJCYS) is a rare, multisystem, bone disease caused by 3 
heterozygous mutations in the NOTCH2 gene. Histomorphometric and bone ultrastructural analyses in 4 
children have not been reported and sparse evidence exists on response to bisphosphonate (BP) 5 
therapy. 6 
Objective: To investigate clinical and bone histomorphometric characteristics, bone matrix 7 
mineralization and the response of bone geometry and density to BP therapy. 8 
Patients: Five children with HJCYS (3 males) aged between 6.7 and 15.3 years. 9 
Interventions: Various BP regimens (pamidronate, zoledronic acid, alendronate) were used for 10 
between one and ten years. 11 
Main Outcome Measures: Pre-treatment transiliac bone biopsy specimens and peripheral quantitative 12 
computed tomography (pQCT) results were available in four and three subjects, respectively. Bone 13 
histomorphometry and quantitative backscattered electron imaging were performed in two patients. 14 
The response to BP was monitored using dual energy X-ray absorptiometry and pQCT. 15 
Results: Three patients had novel NOTCH2 mutations. Histomorphometry demonstrated increased 16 
bone resorption and osteoclast numbers, increased heterogeneity of mineralization and immature, 17 
woven bone. Trabecular bone formation was normal or elevated. Radius cortical thickness and density 18 
and lumbar spine bone mineral density were reduced at baseline and increased in response to BP 19 
therapy, which was not sustained after therapy discontinuation. 20 
Conclusions: Increased bone resorption and low cortical thickness are consistent with the effect of 21 
activating NOTCH2 mutations, which stimulate osteoclastogenesis. The increase in lumbar spine bone 22 
density and radial cortical thickness and density by BP therapy provides evidence of beneficial 23 
treatment effects in children with HJCYS.  24 
25 
  
4 
Précis 1 
High resorption, heterogenous mineralization, woven bone and low cortical thickness are characteristic 2 
of HJCYS bone. Reduced bone density and cortical thickness increased during bisphosphonate 3 
therapy. 4 
5 
  
5 
Introduction 1 
Hajdu-Cheney Syndrome (HJCYS) is a rare multi-system disorder with an autosomal dominant pattern 2 
of inheritance, characterized by acroosteolysis, osteoporosis, short stature, specific craniofacial 3 
features, neurological symptoms, cardiovascular defects and polycystic kidneys (1). The HJCYS 4 
phenotype was originally described by Hajdu in 1948 (2) and expanded by Cheney (3). Since then 5 
various sporadic or familial cases have been reported. HJCYS is caused by mutations in exon 34 of the 6 
NOTCH2 gene, which encodes the Notch2 receptor, a regulator of skeletal development involved in 7 
osteoblast and osteoclast differentiation (4,5). The Notch2 receptor belongs to a family of four (Notch 8 
1–4) transmembrane receptors that play a critical role in cell fate decisions. Notch1 and specifically 9 
Notch2 receptors are considered responsible for the skeletal effects (1,6).  10 
 11 
NOTCH2 mutations in HJCYS result in a receptor protein lacking a predicted C-terminal proline-12 
glutamic acid-serine-threonine-rich (PEST) domain, which normally reduces the half-life of the 13 
encoded protein. Absence of this domain is presumed to yield dominant gain-of-function effects 14 
through increased protein stability and signalling activity (4,5,7), although this has not yet been 15 
verified in functional studies of NOTCH2. The canonical NOTCH pathway is known to modulate cell 16 
fate and function in osteoblast and osteoclast lineages (1,8). In murine models, the activation of Notch 17 
signalling stops the commitment of pluripotent precursors to the osteoblastic lineage, and suppresses 18 
osteoblast differentiation (9). Notch2 mutant mice carrying an equivalent truncating mutation deleting 19 
the putative PEST domain exhibit low bone mass secondary to increased osteoclast numbers and high 20 
bone resorption, shown by the increase in the preosteoclast cell pool, the osteoclastogenic response to 21 
receptor activator of nuclear factor KappaB ligand (Rankl), and tissue Rankl concentrations (10). 22 
 23 
Whilst osteoporosis is a known feature of human HJCYS, little is known regarding the bone tissue 24 
characteristics. Early histological studies in adults were partly inconclusive (11-15). Several reports 25 
have documented histological features of high turnover osteoporosis, with increased resorptive 26 
surfaces and decreased endosteal bone surfaces compared with healthy controls (11-14). To date, 27 
histomorphometric and bone ultrastructural analyses in the developing skeleton of children with 28 
  
6 
HJCYS have not been reported. In addition, while sparse evidence suggests increasing bone mineral 1 
density (BMD) during bisphosphonate (BP) therapy in adults (15-19) and two children (20,21) with 2 
HJCYS, the differential response in bone geometry and density of the axial and appendicular skeleton 3 
has not been illustrated.  4 
 5 
The aim of this study was to investigate clinical and histomorphometric characteristics, bone matrix 6 
mineralization and the response of bone geometry and density to BP therapy in five children with 7 
HJCYS, three of whom had novel NOTCH2 mutations. 8 
 9 
Materials and Methods 10 
Patients 11 
Five children (2 girls, 3 boys) with HJCYS presented to metabolic bone physicians in 12 
Birmingham/UK, Bethesda/USA, Southampton/UK, Rochester/USA and Montreal/Canada. Clinical 13 
information and radiographic data from skeletal surveys were collected at diagnosis. Patients 1, 2, 3 14 
and 5 underwent genetic testing of the NOTCH2 gene; patient 4 had a clinical diagnosis only. 15 
Sequencing was performed using standard methods and data were analyzed using MutationSurveyor 16 
(Soft Genetics, Inc). Trans-iliac bone biopsies were taken following informed consent. All were 17 
treated with various BP regimes with a starting age between 6.7 and 15.3 years, based on reduced 18 
BMD and/or vertebral and limb fractures. Informed consent for genetic studies and publication of 19 
clinical data was obtained from patients or their parents as appropriate. 20 
 21 
Bone histomorphometry and quantitative Backscattered Electron Imaging (qBEI) 22 
Patients 3 and 5 had transiliac bone biopsies taken before the initiation of BP treatment, following 23 
double-labelling with tetracycline to allow for dynamic measurement of bone formation. Samples 24 
were sent to the Genetics Unit of the Shriners Hospital for Children in Montreal, Canada. Sample 25 
preparation and histomorphometric analyses were performed using standard procedures (22). Results 26 
were compared to reference data of healthy age-matched controls (22,23). Subsequently, the residual 27 
blocks were prepared to assess bone mineralization density distribution (BMDD), reflecting the 28 
  
7 
calcium content of cortical and trabecular bone matrix by qBEI and compared to controls as described 1 
previously (24,25,26), at the Ludwig Boltzmann Institute of Osteology in Vienna, Austria.  2 
 3 
Patient 1 also had a pre-treatment transiliac bone biopsy, and patient 4 had a post-treatment biopsy 4 
following 20 months of BP discontinuation. Whilst reports were available, the latter biopsy samples 5 
were either decalcified or not double-labelled, and not available for detailed histomorphometric 6 
analysis. Patient 2 had post-treatment, non-histomorphometric analysis of maxillary bone, as 7 
previously reported [subject HJCYS05 in (27)]. 8 
 9 
Dual energy X-ray absorptiometry (DXA) 10 
Bone mineral density (BMD) of patient 1 was measured using a GE Lunar™ iDXA (GE Medical 11 
Systems, Madison, Wisconsin, US).  Patients 2, 3 and 5 were scanned on a QDR Discovery Hologic™ 12 
(Hologic, Waltham, MA, US), and patient 4 had scans on both DXA models. Lumbar spine scans were 13 
obtained; iDXA scans were analysed using Encore version 13.6 (Basic and Enhanced) and Hologic 14 
scans with Apex 4.1. Lumbar spine BMD results were adjusted for body size by calculating the bone 15 
mineral apparent density (BMAD, g/cm
3
) using the method of Carter et al (28) for GE scanner output, 16 
and by using height-adjusted Z-scores (HAZ) for Hologic scanner output (29). 17 
 18 
Peripheral quantitative computed tomography (pQCT) 19 
pQCT was performed at the distal and proximal radius of the non-dominant forearm (4% and 66% of 20 
radial length, respectively) using a Stratec XCT2000® scanner (Stratec Inc., Pforzheim, Germany) 21 
with voxel size 0.4 mm, slice thickness 2.3 mm and scan speed 25 mm/s. Positioning of the reference 22 
line depending on the presence of a growth plate was performed as previously described (30). Bone 23 
measurements were obtained 4 % proximal to the reference line for total and trabecular vBMD, and at 24 
the 66 % site for cortical vBMD, bone mineral content (BMC), muscle area and cortical thickness. 25 
Cortical thickness was calculated using the manufacturer’s software. Image acquisition, processing 26 
and the calculation of numerical values were performed using the manufacturer's software package 27 
(XCT 6.0). Z-scores were calculated using reference data for the distal (30) and proximal (31,32) 28 
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radius. Patients 1, 3 and 5 had pQCT scans before commencing BP treatment. Repeat pQCT scans 1 
were performed in patient 1 four years after starting BP, and in patient 3 one and 4.5 years after 2 
starting BP.  3 
 4 
Results 5 
Patient clinical characteristics 6 
All patients were born to healthy, non-consanguineous parents. Patients 1, 3 and 5 were found to have 7 
novel heterozygous protein-truncating NOTCH2 gene mutations (reference sequence NM_024408.3): 8 
c.6902T>A (p.Leu2301*), c.6787C>T (p.Gln2263*) and c.6724_6725delAG (p.Ser2242*), 9 
respectively (mutations submitted to ClinVar). Patient 2’s mutation was previously reported (27). In 10 
addition to displaying common features of HJCYS, our patients showed some rarely described (33) 11 
phenotypic features, such as intestinal malrotation, delayed puberty (P1 had late menarche age 19 12 
years with normal oestradiol and LHRH test results) and hip acetabular dysplasia with loss of normal 13 
femoral epiphysis. Their median height Z-score was -1.4 (range -3.5 to -0.4). Patient 1 was wheelchair 14 
dependent, but patients 2-5 had normal mobility. Supplementary Table 1 summarizes the genetic and 15 
phenotypic characteristics of all 5 patients, and Supplementary Table 2 summarizes their radiological 16 
findings.   17 
 18 
Treatment with BP 19 
Patient 1 has been receiving 6-monthly intravenous zoledronate 0.05 mg/kg/dose from the age of 15 20 
years. Patient 2 received 3-monthly intravenous pamidronate 1mg/kg/dose from age 6.8 years for 1 21 
year, and then switched to 35 mg oral alendronate weekly for 3 years, which was increased to 70 mg 22 
weekly for 2.5 years. Following a 5-year interval without any BP treatment, he had one infusion of 5 23 
mg zoledronate at the age of 17.5 years. Patient 3 received 3 doses of 6-monthly zoledronate 0.05 24 
mg/kg/dose at the age of 15.5 years and then refused to have more infusions. Patient 4 started therapy 25 
at the age of 10 years with 5 mg oral daily alendronate, followed by 35 mg weekly from age 13 years, 26 
and 70 mg weekly from age 15 years, which was discontinued at age 20 years.  Following a 2-year 27 
interval without treatment he had 2 more years of 70 mg weekly alendronate. He then stopped BP 28 
  
9 
therapy aged 24 years, due to declining glomerular filtration rate caused by polycystic kidney disease 1 
requiring renal transplantation at age 25 years. Patient 5 (10 years) has just started therapy with 4-2 
monthly intravenous pamidronate 1.5 mg/kg/d for 2 days. 3 
 4 
Bone Histomorphometry  5 
Table 1 shows the results of histomorphometric parameters from pre-BP treatment transiliac bone 6 
samples of patients 3 (male) and 5 (female). Histological images are depicted for both patients and a 7 
control in Figure 1a-1c. The cortex was the most abnormal structural bone parameter in biopsy 8 
samples of Patients 3 and 5. Cortical width was 55 % of the mean for age in Patient 5. The cortices in 9 
Patient 3 appeared highly porous or trabecularized with no clear distinction between the cancellous 10 
and cortical compartment to the extent that cortical width was not measurable (Figure 1a). Trabecular 11 
number and cancellous bone volume was elevated only in patient 3, but average for age in patient 5. 12 
There was no hyperosteocytosis. Patient 5’s trabecular compartment contained a few areas with woven 13 
bone nodules (Figure 1d) but the large majority of trabeculae consisted of lamellar bone. 14 
 15 
Static parameters of bone formation showed that osteoblast surface/bone surface was 320 % and 170 16 
% of the mean for age in patient 3 and 5, respectively. Osteoid thickness was above the reference 17 
range for age in Patient 5, but normal in patient 3. Dynamic parameters of bone formation showed 18 
inconsistent findings: patient 3’s sample had a clearly elevated mineralization surface/bone surface 19 
and bone formation rate whilst these parameters were within the normal range in patient 5’s sample. 20 
There was no mineralization defect in either of the patients.  21 
 22 
Consistent in both samples was evidence for high bone resorption activity. Eroded surface was 183 % 23 
and 176 % of the mean for age in Patient 3 and 5, and the number of osteoclasts was 200 % and 175 24 
%, respectively. 25 
 26 
Patient 1’s pre-treatment and patient 4’s 20-months post-treatment bone biopsies were reported to 27 
show high bone resorption, but biopsies were not available for systematic histomorphometric analysis. 28 
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 1 
Bone mineralization density distribution (BMDD) (Table 2, Figure 2) 2 
Quantitative Backscattered images from Patient 3 revealed highly trabecularized cortices (Figure 2a) 3 
which was not observed in Patient 5 (Figure 2 b). 4 
 5 
Trabecular Bone 6 
Cancellous bone from patients 3 and 5 showed a slight tendency towards higher matrix mineralization 7 
as mirrored by the peak position (CaPeak) of the BMDD (Figures 2c,d). CaWidth was elevated, 8 
demonstrating greater heterogeneity in mineralization, with increased percentage of poorly 9 
mineralized bone (CaLow) in both patients, and increased percentage of highly mineralized bone 10 
(CaHigh) in Patient 5 (Table 2), compared to reference populations (26). 11 
 12 
Cortical Bone 13 
The CaPeak position of patient 3 was in the normal range, but slightly shifted towards lower bone 14 
matrix mineralization in patient 5, compared to controls (Figures 2e,2f). CaWidth was again elevated, 15 
demonstrating greater heterogeneity in mineralisation, with increased percentage of highly mineralized 16 
bone (CaHigh) in both samples, and a greater percentage of poorly mineralized bone (CaLow) in 17 
patient 5, compared to reference population (26). (Table2).  18 
 19 
Lumbar spine bone density before and during BP treatment 20 
Age-, gender-, and size-adjusted lumbar spine bone density Z-scores (BMAD, HAZ) were below 21 
average before treatment in all patients, ranging from -0.5 to -3.4 (median–1.3). These Z-scores 22 
increased during BP treatment, with median ΔZ-score of +0.7 (0.1 to 1) after 1 year of treatment and a 23 
peak change of +1.5 (0.1 to 3.3) during treatment.  However, after discontinuation of treatment HAZ 24 
dropped again from 0.3 to -2.5 in Patient 2, and from -0.7 to -1.1 in patient 3 (Figure 3). BP treatment 25 
was not restarted in patient 2 due to multiple dental procedures. Patient 4 had the greatest initial 26 
increase in rise in BMD, which was not sustained on oral alendronate. His BMD dropped after each 27 
BP treatment discontinuation but his clinical course was also complicated by progressive renal failure. 28 
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 1 
pQCT results before and during BP treatment 2 
Table 3 demonstrates pQCT data at baseline (patients 1, 3 and 5), during zoledronate therapy (patients 3 
1, 3) and following its discontinuation (patient 3). The common characteristic baseline feature of all 4 
three patients is the very low cortical density Z-score (-4.3, -4.9, -3.7, respectively), as well as low 5 
cortical thickness (-2.3, -1.1, -2.3, respectively). During zoledronate therapy, cortical density increased 6 
in both patients (patient 1: 984 mg/cm
3
 to 1022 mg/cm
3
, patient 3: 885 mg/cm
3
 to 1029 mg/cm
3
), 7 
although patient 1’s value did not increase relative to reference data (Z-score pre-treatment: -4.3, after 8 
4 years of treatment: -4.9). Patient 3’s cortical density continued to improve even after the 9 
discontinuation of zoledronate (Z-score -2.5). Cortical thickness Z-score increased significantly with 10 
treatment in patients 1 and 3 and decreased again in patient 3 following treatment discontinuation. In 11 
contrast to the low cortical bone thickness and density at the proximal radius, trabecular and total bone 12 
density at the distal radius were relatively normal. Surprisingly, total and trabecular density Z-scores 13 
decreased during BP therapy in patient 1 but increased in patient 3, and dropped to very low levels 14 
after treatment discontinuation. 15 
 16 
Fractures and progress of acroosteolysis 17 
At start of BP therapy, patients 1, 3 and 5 had multiple vertebral fractures and patients 1 and 2 had 18 
long bone fractures (P1: tibia/fibula, P2: radius/ulna) whilst patient 4 had no fractures. During therapy, 19 
patient 4 developed vertebral and metatarsal fractures and patient 3 sustained a tibia fracture, while P1 20 
and P2 sustained no new fractures. Patient 2 developed fractures of fingers and metatarsals after 21 
treatment cessation. Mild undertubulation of the metaphyses were observed in patient 2 during 22 
treatment, and as treatment did not appear to slow the progression of acroosteolysis, BP therapy was 23 
paused. The forth fingers were spared bilaterally. Since reaching skeletal maturity, acroosteolysis has 24 
remained stable (currently aged 21y). In contrast, patient 4 showed slower progression of 25 
acroosteolysis during BP treatment, compared to before treatment. No details are available on the 26 
progression of acroosteolysis in patients 1, 3 or 5. 27 
 28 
  
12 
Discussion 1 
The results of this study indicate a unique bone tissue phenotype of patients with HJCYS, 2 
characterized by increased bone resorption, with or without increased trabecular bone formation, a 3 
greater than normal heterogeneity in mineralization, and immature, woven bone. Structurally, 4 
activating NOTCH2 mutations appear to affect appendicular cortical bone more than trabecular bone. 5 
The markedly reduced cortical thickness and density and lumbar spine BMD increase substantially in 6 
response to BP therapy, indicating that affected individuals benefit from anti-resorptive therapy. This 7 
report also adds three novel NOTCH2 mutations to the literature. 8 
 9 
Limited bone histological analyses from affected adults have highlighted HJCYS as a form of high 10 
turnover osteoporosis, but the older literature is inconclusive (11-14,27). Increased bone resorption 11 
certainly was a hallmark finding in tissue samples of our patients. Elevated resorption markers were 12 
previously reported in HJCYS subjects (14). Bone formation appeared less affected than resorption in 13 
histomorphometric analysis. In fact, while patient 5 had normal static and dynamic parameters of bone 14 
formation, patient 3 had elevated amounts of trabecular bone with increased bone formation. 15 
Decreased trabecular bone volume was previously only described in very young HJCYS mouse 16 
mutants who show no defect in OB differentiation or their bone-forming capacity in vitro from age 3 17 
months (10). Hence, the predominantly cortical rather than trabecular bone defect we observed may be 18 
a result of compartment-specific differential regulation by Notch signalling (10), with increased 19 
endocortical bone resorption leading to thinning and trabecularisation of the cortices. Alternatively, 20 
the normal or increased trabecular numbers could potentially be a biomechanical compensation for 21 
reduced cortical bone, or the result of variable expressivity of modifier genes. 22 
 23 
Apart from excessive bone resorption, the other common feature was the more heterogeneous matrix 24 
mineralization, caused by variably increased proportions of poorly and/or highly mineralized bone in 25 
both cortical and trabecular bone. Despite normal or increased bone formation, matrix mineralization 26 
in cancellous bone was slightly right-shifted (towards higher mineral content of the bone matrix) 27 
rather than left-shifted, as one would expect with high bone turnover (25). Possibly, the increased 28 
  
13 
matrix mineralization heterogeneity might be due to the presence of densely mineralized woven bone 1 
within normal bone tissue (34,35). Indeed, patient 5 was found to have immature, woven bone, a 2 
finding previously described in a maxillary bone specimen from patient 2 when he was 14 years old 3 
(27). The presence of woven bone likely represents a typical feature of NOTCH2-mutated bone, since 4 
it is also present in Notch2-mutated mice and associated with increased proliferation of immature 5 
osteoblasts (36). 6 
 7 
The most striking new finding on bone imaging was the uniformly low cortical thickness and density 8 
in all patients undergoing pQCT scanning (n=3), which is consistent with the trabecularization of the 9 
cortex seen on biopsy. Low cortical thickness and high cortical porosity are also features of the 10 
Notch2-mutated mouse (10). This finding fits the histologically evident excessive resorption rather 11 
than a formation defect, a hypothesis supported by observation of increasing cortical thickness during 12 
BP therapy in this study.  13 
 14 
The increased osteoclast number and bone resorption in mice with activating HJCYSNotch2 mutations 15 
is in accordance with our histomorphometric findings. However, Patient 3 had increased trabecular 16 
bone and trabecularization of the cortex as reported in the appendicular skeleton of mouse models with 17 
OB-specific Notch2 inactivation (37,38). This counterintuitive result gives rise to speculation of 18 
variable gene expressivity and post-receptor interactions in osteoblast and osteoclasts. In addition, age 19 
and gender may also play a role, as demonstrated in mouse models (37,39). Of note, Notch pathway 20 
activation in osteocytes leads to induction of Opg expression and Wnt/β-catenin signaling, with a 21 
consequent suppression of bone resorption in cancellous bone, and enhancement of bone formation in 22 
cortical bone (7).  23 
 24 
The natural evolution of HJCYS leads to significant osteoporosis with vertebral compression fractures 25 
and continuous deterioration of acroosteolysis (11, 19, 40, 41). A previous report following 2 patients 26 
with HJCYS for 17 years without any treatment, showed a dramatic decrease in height and chronic 27 
back pain due to progression of vertebral fractures, alongside a decrease in BMD. The progression of 28 
  
14 
acroosteolysis continued during follow-up (11). The mechanism of disease for acroosteolysis in 1 
HJCYS is poorly understood. Samples containing acroosteolysis showed increased osteoclastic bone 2 
resorption and reduced bone formation (14) whilst others had high numbers of mast cells and 3 
neovascularisation with absent osteoclasts (12, 42). Acroosteolysis seemed to progress in patient 2 4 
despite BP therapy and plateaued post puberty but showed slower progression in patient 4, reinforcing 5 
the suggestion of a disease mechanism other than osteoclastic bone resorption (21). 6 
 7 
There are no controlled trials on the management of osteoporosis in HJCYS, apart from anecdotal 8 
cases treated with BPs, teriparatide or denosumab (15-20). Taking into consideration that elevated 9 
bone resorption is the main feature in the pathogenesis of osteoporosis in HJCYS, BPs are the logical 10 
therapeutic option in these patients, as they lead to osteoclast apoptosis (43). Accordingly, BPs have 11 
become the primary therapy for managing skeletal conditions characterized by increased osteoclast-12 
mediated bone resorption. Here, we show the improvement in height-adjusted lumbar spine BMD z-13 
scores and cortical thickness in treated patients. However, relatively fast reversibility of treatment 14 
benefit was observed soon after treatment discontinuation as demonstrated in patients 2 (by DXA), 3 15 
(by DXA and pQCT) and 4 (by DXA and post-BP biopsy). This reversibility appears more 16 
pronounced compared to data from children with osteogenesis imperfecta (44). The BMD increase 17 
during BP treatment is in accordance with most cases of BP therapy in adults (16,17), apart from one 18 
case where glucocorticoids were co-administered (15). In children with HJCYS, there are only two 19 
case reports of intravenous BP therapy, which showed substantial improvement in lumbar spine BMD, 20 
a 9 % gain over 1 year in a 13-year old boy (21) and 67 % gain over 2 years in a 9-year old girl (20). 21 
Bone resorption markers also decrease during BP therapy (15,16). Overall, the results of this study and 22 
the existing literature support the use of intravenous BP therapy in patients with HJCYS. Given the 23 
association of HJCYS with renal disease (1) and the nephrotoxicity of zoledronate, renal function 24 
should be monitored during BP therapy. Anti-resorptive therapy with denosumab may also be 25 
beneficial (18). 26 
 27 
  
15 
While it is reasonable to assume that fracture risk decreases during BP therapy, such evidence will be 1 
difficult to collect in such an ultra-rare disease. Treatment guidelines on type and duration of anti-2 
resorptive therapy will need to be established, including systematic observation of acroosteolysis, in a 3 
rare bone disease registry. HJCYS clearly is a multi-system disorder, demonstrating that NOTCH2 4 
activation affects development and function of several organs.  5 
 6 
In conclusion, this study demonstrates increased bone resorption, increased heterogeneity of bone 7 
matrix mineralization, woven bone, and reduced cortical thickness as typical bone characteristics of 8 
HJCYS. These features are consistent with the effect of presumptive activating NOTCH2 mutations on 9 
osteoclastogenesis and cortical bone described in mouse models. Here, we demonstrate that 10 
intravenous BP therapy increased size-corrected lumbar spine BMD and radial cortical thickness and 11 
density, which provides further evidence of beneficial treatment effects in children with HJCYS. Since 12 
treatment effects were not sustained after BP discontinuation, further studies are needed to inform 13 
guidance on treatment dose and duration. Whether acroosteolysis can be improved with BP therapy 14 
remains to be elucidated. From a clinical management perspective, the bone phenotype of our patients 15 
at baseline suggests, similar to other paediatric conditions with high bone resorption, that early 16 
diagnosis, including assessment for vertebral fractures, is essential so that therapy can be started 17 
earlier in life. 18 
 19 
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Figure Legends: 
 
Figure 1. Histological images (Goldner Trichome staining) from transiliac bone biopsies naïve to 
bisphosphonate therapy. a) Patient 3 (male, 15y): note increased trabecular density compared to 
control and trabecularization of the cortex (arrow); b) Patient 5 (female, 10y): note the relatively 
thin cortex and normal trabecular bone, c) Healthy control sample (female, 9.4y); d.) Patient 5: 
note the presence of woven bone (arrow) which is atypical in this location. 
 
Figure 2. Quantitative backscattered images depicting cortical dimensions and trabecular network 
(a,b), and BMDD histograms of cancellous (c,d) and cortical bone (e,f) from transiliac biopsy 
samples of patient 3 (left panels) and 5 (right panels). BMDD results of cancellous and cortical 
bone are compared to reference BMDD from healthy children (gray band) (26). The 
corresponding parameters are given in Table 2. 
 
Figure 3. Age-, gender- and size-adjusted lumbar spine BMD Z-scores in response to 
bisphosphonate therapy in Patients 1-4. BMAD Z-scores are used for patients measured on Lunar 
scanners and HAZ for patients on Hologic scanners. Arrows pointing downwards indicate 
treatment discontinuation, arrows pointing upwards treatment restart. For details on dose and 
choice of bisphosphonate therapy please refer to text. 
 
Table Legend: 
 
Table 2: CaMean, the weighted mean calcium concentration of the bone area; CaPeak, the peak 
position of the histogram that indicates the most frequently occurring calcium concentration of the 
bone area; CaWidth, the full width at half maximum of the distribution, describing the variation in 
mineralization density; CaLow, fraction of poorly mineralized bone area defined as the percentage 
of the area below 17.68 wt% Ca, corresponding to the 5th percentile of adult reference BMDD; 
CaHigh, fraction of highly mineralized bone defined as the percentage of bone area that is 
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mineralized above 25.30 wt% Ca, corresponding to the 95th percentile of the adult reference 
range) (25).  Reference data are mean (±1SD) or median with interquartile range [25%; 75%]. 
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